Safety of and Immune Response to the PENNVAX-B DNA Vaccine With and Without IL-12 in HIV-uninfected Adults

HIV Infections Clinical Trial

Official title:

A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of PENNVAX™-B (Gag, Pol, Env) Vaccine, With or Without IL-12 DNA Plasmid, Delivered Via Electroporation in Healthy, HIV-1-Uninfected Adult Participants

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00991354
• Other study ID #: HVTN 080
• Secondary ID: 10741
• Status: Completed
• Phase: Phase 1
• Start date: November 2009
• Est. completion date: March 2011

Study information

• Verified date: October 2021
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

An effective vaccine may be the only way to stop the HIV pandemic. The purpose of this study is to determine the safety of and immune response to the DNA vaccine, PENNVAX-B with or without an IL-12 adjuvant when given using electroporation.

Description:

An effective and safe vaccine must be developed in order to halt the HIV pandemic. The purpose of this study is to assess the safety and immune response to the HIV DNA vaccine, PENNVAX-B when given with and without an IL-12 adjuvant and delivered via electroporation.

Participants in this study will be randomly assigned to one of three groups and will visit the study clinic 9 times over 9 months. Group 1 will enroll first. Participants in this group will receive 3 mg of the PENNVAX-B or placebo vaccine at Months 0, 1, and 3. Once safety data has been examined for Group 1, Group 2 will begin enrollment. Group 2 participants will receive 3 mg of PENNVAX-B vaccine plus 1 mg of IL-12 adjuvant or placebo at Months 0, 1, and

3. Once Group 1 and Group 2 safety data have been collected Group 3 will begin enrollment. These participants will also receive 3 mg of PENNVAX-B vaccine plus 1 mg of IL-12 adjuvant or placebo at Months 0, 1, and 3.

At clinic visits participants will have physical exams and blood and urine collected. After receiving study injections, participants will be observed in the clinic for at least 30 minutes. In addition, participants will be asked to monitor symptoms for 3 days after each injection.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: March 2011
• Est. primary completion date: February 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Access to a participating HVTN CRS and willingness to be followed for the planned duration of the study

• Ability and willingness to provide informed consent

• Assessment of understanding: volunteer demonstrates understanding of this study and the Step Study results; completes a questionnaire prior to first vaccination, with verbal demonstration of understanding of all questionnaire items answered incorrectly

• Willing to receive HIV test results

• Willingness to discuss HIV infection risks, amenable to risk reduction counseling, committed to maintaining behavior consistent with low risk of HIV exposure through the last required protocol clinic visit

• Assessed by the clinic staff as being at "low risk" for HIV infection on the basis of behaviors within the 12 months prior to enrollment

• Good general health as shown by medical history, physical exam, and screening laboratory tests

• Certain laboratory values. Details on this criterion can be found in the protocol.

• Negative HIV-1 and -2 blood test: US participants must have a negative FDA-approved enzyme immunoassay (EIA).

• Negative Hepatitis B surface antigen (HBsAg)

• Negative anti-Hepatitis C virus antibodies (anti-HCV), or negative HCV polymerase chain reaction (PCR) if the anti-HCV is positive

• Volunteers who were born female: negative serum or urine beta human chorionic gonadotropin (ß-HCG) pregnancy test performed prior to vaccination on the day of initial vaccination

• Reproductive status: A volunteer who was born female must agree to consistently use effective contraception from at least 21 days prior to enrollment through the last required protocol clinic visit for sexual activity that could lead to pregnancy, or not be of reproductive potential, or be sexually abstinent

• Volunteers who were born female must also agree not to seek pregnancy through alternative methods, such as artificial insemination or in vitro fertilization until after the last required protocol clinic visit

Exclusion criteria:

• Within the 12 months prior to enrollment: excessive daily alcohol use or frequent binge drinking or chronic marijuana abuse or any other illicit drug use

• Within the 12 months prior to enrollment: a history of newly acquired or diagnosed syphilis; newly acquired gonorrhea, non-gonococcal urethritis, herpes simplex virus type 2 (HSV2), chlamydia, pelvic inflammatory disease (PID), trichomonas, mucopurulent cervicitis, epididymitis, proctitis, lymphogranuloma venereum, or chancroid

• Untreated or incompletely treated syphilis infection

• HIV vaccine(s) received in a prior HIV vaccine trial. For potential participants who have received control/placebo in an HIV vaccine trial, documentation of the identity of the study control/placebo must be provided to the HVTN 080 PSRT, who will determine eligibility on a case-by-case basis.

• Non-HIV experimental vaccine(s) received within the last 5 years in a prior vaccine trial. Exceptions may be made for vaccines that have subsequently undergone licensure by the FDA or for those who have received control/placebo in an experimental vaccine trial.

• Immunosuppressive medications received within 168 days before first vaccination. (Not excluded: [1] corticosteroid nasal spray for allergic rhinitis; [2] topical corticosteroids for mild, uncomplicated dermatitis or [3] oral/parenteral corticosteroids given for non-chronic conditions not expected to recur [length of therapy 10 days or less with completion at least 30 days prior to enrollment])

• Blood products received within 120 days before first vaccination

• Immunoglobulin received within 60 days before first vaccination

• Live attenuated vaccines other than influenza vaccine received within 30 days before first vaccination or scheduled within 14 days after injection

• Investigational research agents received within 30 days before first vaccination

• Intent to participate in another study of an investigational research agent during the planned duration of the HVTN 080 study

• Influenza vaccine or any vaccines that are not live attenuated vaccines and were received within 14 days prior to first vaccination (e.g., tetanus, pneumococcal, Hepatitis A or B, HPV)

• Allergy treatment with antigen injections within 30 days before first vaccination or that are scheduled within 14 days after first vaccination

• Current anti-tuberculosis (TB) prophylaxis or therapy

• Allergy to amide-type local anesthetics

• Presence of implanted electronic medical device (e.g., pacemaker, implantable cardioverter defibrillator)

• A history of cardiac arrhythmia, e.g., supraventricular tachycardia, atrial fibrillation, or frequent ectopy on exam. (Not excluded: sinus arrhythmia)

• Clinically significant medical condition, physical examination findings, clinically significant abnormal laboratory results, or past medical history with clinically significant implications for current health.

• Any medical, psychiatric, occupational, or other condition that, in the judgment of the investigator, would interfere with, or serve as a contraindication to, protocol adherence, assessment of safety or reactogenicity, or a participant's ability to give informed consent

• Serious adverse reactions to vaccines including anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema, and/or abdominal pain.

• Autoimmune disease

• Immunodeficiency

• Asthma other than mild, well-controlled asthma.

• Diabetes mellitus type 1 or type 2, including cases controlled with diet alone. (Not excluded: history of isolated gestational diabetes.)

• Thyroidectomy, or thyroid disease requiring medication during the last 12 months

• Angioedema within the last 3 years if episodes are considered serious or have required medication within the last 2 years

• Hypertension

• BMI > 30 kg/m2

• Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions)

• Malignancy (Not excluded: a participant with a surgical excision and subsequent observation period that in the investigator's estimation has a reasonable assurance of sustained cure or is unlikely to recur during the period of the study.)

• Seizure disorder

• Asplenia: any condition resulting in the absence of a functional spleen

• Psychiatric condition that precludes compliance with the protocol

• Pregnant or breastfeeding

Related Conditions & MeSH terms

• HIV Infections

Intervention

Biological:
• PENNVAX-B
DNA vaccine encoding the Gag, Pol, and Env proteins of HIV
• IL-12 DNA plasmids
Adjuvant for HIV vaccines

Locations

Country	Name	City	State
United States	Vanderbilt Vaccine CRS	Nashville	Tennessee
United States	3535 Market Street CRS	Philadelphia	Pennsylvania
United States	Univ. of Rochester HVTN CRS	Rochester	New York

Sponsors (1)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Frequency and severity of local injection/EP site reactogenicity signs and symptoms		Throughout study
Primary	Magnitude of local injection/EP site pain as measured by a VAS		Throughout study
Primary	Frequency of AEs categorized by MedDRA body system, MedDRA preferred term, severity and assessed relationship to study products; detailed description of all AEs meeting DAIDS criteria for expedited reporting		Throughout study
Primary	WBC, neutrophils, lymphocytes, hemoglobin, alkaline phosphatase, platelets, ALT, AST, creatinine, and creatine phosphokinase (CPK)		At baseline and post-vaccinations
Primary	Number of participants with early discontinuation of vaccinations and reason for discontinuation		Throughout study
Primary	Distribution of responses to questions regarding acceptability of study injections via EP		Throughout study
Secondary	Frequency of T-cell responses as measured by IFN-? ELISpot		Two Weeks after the second and third vaccinations
Secondary	Frequency of CD4+ T cell responses measured by intracellular cytokine staining (ICS) for IFN-? and/or IL-2 to HIV potential T-cell epitope (PTE) peptide pools representing Gag, Pol, and Env		After the second and third vaccinations
Secondary	Frequency of CD8+ T cell responses measured by ICS for IFN-? and/or IL-2 to HIV PTE peptide pools representing Gag, Pol, and Env		After the second and third vaccinations
Secondary	Frequency of humoral responses detected by HIV-1-specific neutralizing and binding antibody assays from serum samples		Two weeks after last vaccination
Secondary	Frequency of vaccine-induced positive results with end-of-study HIV serological testing by commercial assays		Throughout study